PrEvention of posttraumatic contractuRes with Ketotifen 2 (PERK 2) - protocol for a multicenter randomized clinical trial

• Published in: BMC musculoskeletal disorders Vol. 21; no. 1; p. 123
• Main Authors: Ademola, Ayoola, Hildebrand, Kevin A, Schneider, Prism S, Mohtadi, Nicholas G H, White, Neil J, Bosse, Michael J, Garven, Alexandra, Walker, Richard E A, Sajobi, Tolulope T
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 24.02.2020; BioMed Central; BMC
• Subjects: Adolescent; Adult; Anesthesia; Arthritis; Asthma; Bone healing; Clinical trials; Contracture - diagnosis; Contracture - etiology; Contracture - prevention & control; Contractures; DASH; Dislocations; Double-Blind Method; Drug therapy; Elbow; Female; Fibrosis; Fracture repair; Fractures (Injuries); Fractures, Bone - complications; Fractures, Bone - diagnosis; Fractures, Bone - drug therapy; Grooming; Histamine H1 Antagonists - administration & dosage; Humans; Humerus; Injuries; Intervention; Joint diseases; Joint Dislocations - complications; Joint Dislocations - diagnosis; Joint Dislocations - drug therapy; Ketotifen; Ketotifen - administration & dosage; Ketotifen Fumarate; Lactose; Male; Musculoskeletal diseases; Neuropeptides; OES; Pain; PCS; Population studies; Prevention; Proms (Parties); Quality of life; Range of motion; RCT; Study Protocol; Surgeons; Surgical outcomes; Surveillance; Testing; Trauma; X-rays; Young Adult; Canada; United States > US; Calgary Alberta Canada; PCS; ROM; RCT; Contractures; OES; DASH; Ketotifen Fumarate
• ISSN: 1471-2474; 1471-2474
• DOI: 10.1186/s12891-020-3139-2

Injuries and resulting stiffness around joints, especially the elbow, have huge psychological effects by reducing quality of life through interference with normal daily activities such as feeding, dressing, grooming, and reaching for objects. Over the last several years and through numerous research results, the myofibroblast-mast cell-neuropeptide axis of fibrosis had been implicated in post-traumatic joint contractures. Pre-clinical models and a pilot randomized clinical trial (RCT) demonstrated the feasibility and safety of using Ketotifen Fumarate (KF), a mast cell stabilizer to prevent elbow joint contractures. This study aims to evaluate the efficacy of KF in reducing joint contracture severity in adult participants with operately treated elbow fractures and/or dislocations. A Phase III randomized, controlled, double-blinded multicentre trial with 3 parallel groups (KF 2 mg or 5 mg or lactose placebo twice daily orally for 6 weeks). The study population consist of adults who are at least 18 years old and within 7 days of injury. The types of injuries are distal humerus (AO/OTA type 13) and/or proximal ulna and/or proximal radius fractures (AO/OTA type 2 U1 and/or 2R1) and/or elbow dislocations (open fractures with or without nerve injury may be included). A stratified randomization scheme by hospital site will be used to assign eligible participants to the groups in a 1:1:1 ratio. The primary outcome is change in elbow flexion-extension range of motion (ROM) arc from baseline to 12 weeks post-randomization. The secondary outcomes are changes in ROM from baseline to 6, 24 & 52 weeks, PROMs at 2, 6, 12, 24 & 52 weeks and impact of KF on safety including serious adverse events and fracture healing. Descriptive analysis for all outcomes will be reported and ANCOVA be used to evaluate the efficacy KF over lactose placebo with respect to the improvement in ROM. The results of this study will provide evidence for the use of KF in reducing post-traumatic joint contractures and improving quality of life after joint injuries. This study was prospectively registered (July 10, 2018) with ClinicalTrials.gov reference: NCT03582176.